In the fourth part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, discusses how healthcare ...

HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a ...

Padcev-Keytruda will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Pfizer stock currently trades at very low volatility. That could mean it’s ripe for a breakout trade, like a long strangle.

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate PFE stock a Sell.

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

In separate multidistrict litigation dockets over injectible birth control Depo-Provera and toxic chemicals in drinking water, federal judges ordered plaintiffs’ lawyers to file their lawsuits after ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...

The AAP published its own vaccine schedule in a break from federal guidance. HHS secretary RFK Jr. took to social media to respond.

West Virginia Attorney General J.B. McCuskey has asked that two lawsuits filed in separate county circuit courts over Gov.

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...